- Home
- TPST vs CVKD Comparison
TPST vs CVKD Comparison
Compare TPST & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- CVKD
- Stock Information
- Founded
- TPST 2011
- CVKD 2022
- Country
- TPST United States
- CVKD United States
- Employees
- TPST N/A
- CVKD N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- TPST Health Care
- CVKD Health Care
- Exchange
- TPST Nasdaq
- CVKD Nasdaq
- Market Cap
- TPST 33.0M
- CVKD 29.5M
- IPO Year
- TPST N/A
- CVKD 2023
- Fundamental
- Price
- TPST $7.09
- CVKD $10.28
- Analyst Decision
- TPST Hold
- CVKD Strong Buy
- Analyst Count
- TPST 3
- CVKD 1
- Target Price
- TPST $30.00
- CVKD $32.00
- AVG Volume (30 Days)
- TPST 245.0K
- CVKD 23.0K
- Earning Date
- TPST 08-07-2025
- CVKD 08-06-2025
- Dividend Yield
- TPST N/A
- CVKD N/A
- EPS Growth
- TPST N/A
- CVKD N/A
- EPS
- TPST N/A
- CVKD N/A
- Revenue
- TPST N/A
- CVKD N/A
- Revenue This Year
- TPST N/A
- CVKD N/A
- Revenue Next Year
- TPST N/A
- CVKD N/A
- P/E Ratio
- TPST N/A
- CVKD N/A
- Revenue Growth
- TPST N/A
- CVKD N/A
- 52 Week Low
- TPST $5.35
- CVKD $5.70
- 52 Week High
- TPST $30.03
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- TPST 49.91
- CVKD 24.53
- Support Level
- TPST $6.87
- CVKD $10.00
- Resistance Level
- TPST $7.25
- CVKD $13.30
- Average True Range (ATR)
- TPST 0.67
- CVKD 0.89
- MACD
- TPST -0.02
- CVKD -0.39
- Stochastic Oscillator
- TPST 11.20
- CVKD 4.67
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.